Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (181-190 of 391) with videos related to

Pageof 40
Sort By:
ERJ Open Research|June 24, 2025
Circulating prostasin is an independent marker of mortality risk in patients with idiopathic pulmonary fibrosisJamie L Todd, Courtney Page, Peitao Wu, et al.
ERJ Open Research|June 1, 2023
Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptationsSteve Jones, Maxine Flewett, Ron Flewett, et al.
Rheumatology (Oxford, England)|May 31, 2022
Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung diseaseMichael Kreuter, Anna-Maria Hoffmann-Vold, Marco Matucci-Cerinic, et al.
The Lancet. Respiratory Medicine|May 25, 2018
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trialToby M Maher, Ellen M van der Aar, Olivier Van de Steen, et al.
Respiratory Research|February 2, 2017
Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosisPhilip L Molyneaux, Michael J Cox, Athol U Wells, et al.
Respirology (Carlton, Vic.)|November 16, 2017
Phenotypic characteristics associated with slow gait speed in idiopathic pulmonary fibrosisClaire M Nolan, Matthew Maddocks, Toby M Maher, et al.
The American Journal of Surgical Pathology|September 7, 2017
Pleuroparenchymal Fibroelastosis: A Review of Histopathologic Features and the Relationship Between Histologic Parameters and SurvivalReena Khiroya, Claudio Macaluso, Maria A Montero, et al.
Respiratory Research|February 8, 2018
The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosisOmar S Usmani, Martyn F Biddiscombe, Shuying Yang, et al.
Respiratory Research|November 11, 2022
A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung diseaseToby M Maher, Courtney Schiffman, Michael Kreuter, et al.
The Lancet. Respiratory Medicine|October 4, 2019
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trialToby M Maher, Tamera J Corte, Aryeh Fischer, et al.
Pageof 40

Showing results (181-190 of 391) with videos related to

Sort By:
Pageof 40
ERJ Open Research|June 24, 2025
Circulating prostasin is an independent marker of mortality risk in patients with idiopathic pulmonary fibrosisJamie L Todd, Courtney Page, Peitao Wu, et al.
ERJ Open Research|June 1, 2023
Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptationsSteve Jones, Maxine Flewett, Ron Flewett, et al.
Rheumatology (Oxford, England)|May 31, 2022
Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung diseaseMichael Kreuter, Anna-Maria Hoffmann-Vold, Marco Matucci-Cerinic, et al.
The Lancet. Respiratory Medicine|May 25, 2018
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trialToby M Maher, Ellen M van der Aar, Olivier Van de Steen, et al.
Respiratory Research|February 2, 2017
Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosisPhilip L Molyneaux, Michael J Cox, Athol U Wells, et al.
Respirology (Carlton, Vic.)|November 16, 2017
Phenotypic characteristics associated with slow gait speed in idiopathic pulmonary fibrosisClaire M Nolan, Matthew Maddocks, Toby M Maher, et al.
The American Journal of Surgical Pathology|September 7, 2017
Pleuroparenchymal Fibroelastosis: A Review of Histopathologic Features and the Relationship Between Histologic Parameters and SurvivalReena Khiroya, Claudio Macaluso, Maria A Montero, et al.
Respiratory Research|February 8, 2018
The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosisOmar S Usmani, Martyn F Biddiscombe, Shuying Yang, et al.
Respiratory Research|November 11, 2022
A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung diseaseToby M Maher, Courtney Schiffman, Michael Kreuter, et al.
The Lancet. Respiratory Medicine|October 4, 2019
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trialToby M Maher, Tamera J Corte, Aryeh Fischer, et al.
Pageof 40